Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

SIGA vs GOVX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SIGA Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

SIGA Overall Winner 6-Pillar Tally: SIGA 6 – 0 GOVX Matrix Metrics: SIGA 7 – 3 GOVX

As of Nov 19, 2026, SIGA Technologies Inc. (SIGA) is the stronger overall head-to-head candidate over GeoVax Labs, Inc. New (GOVX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SIGA carries a Unified Composite Score of 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin), whereas GOVX carries 26.5/100 (SELL) at $1.91 (9.7x Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile GOVX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 72.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SIGA vs GOVX
SIGA NASDAQ Head-to-Head Winner
SIGA Technologies Inc.
Pharmaceutical Preparations
$2.65
-5.36% 1D
Market Cap $187.9M
TTM Revenue $52M
Forward P/E 2.5x
Beta / 30D Vol 0.75β · 65% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.7%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $3.02 · SMA50: $3.14
GOVX NASDAQ
GeoVax Labs, Inc. New
Pharmaceutical Preparations
$1.91
-4.02% 1D
Market Cap $1.1M
TTM Revenue N/A
Forward P/E 9.7x
Beta / 30D Vol 16.91β · 6225% Vol
Unified Composite Score
26.5 / 100 SELL
Tech 50.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (17.5% over 20 days), RSI 72
RSI-14: 72.2 · SMA20: $0.80 · SMA50: $0.51

6-Pillar Scorecard Institutional Category Breakdown (SIGA 6 – 0 GOVX)

Columns: Metric · SIGA · GOVX
1. Valuation Multiples SIGA
Forward P/E 2.5x 9.7x
Trailing P/E N/M 9.7x
PEG Ratio 3.37x N/M
EV / Revenue 1.4x N/M
2. Growth & Scale SIGA
Revenue Growth (YoY) -49.7% -100.0%
Earnings Growth (YoY) -65.3% +0.0%
TTM Revenue (USD) $52M N/A
Market Cap $187.9M $1.1M
3. Profitability & Quality SIGA
Gross Margin 23.4% N/A
Operating Margin -14.2% 0.0%
Net Profit Margin 1.3% 0.0%
Return on Equity (ROE) 0.4% -891.6%
4. Balance Sheet & Cash Flow SIGA
Cash Generation (TTM) -$12M N/A
Cash Flow Margin -22.1% N/A
Net Cash / Leverage $116M Net Cash $2.8M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SIGA
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 81.4% (8th %ile) N/A (N/A)
Put/Call OI Skew 0.04x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat SIGA
OpEx & R&D Intensity 37.6% of Rev ($20M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SIGA (7) vs GOVX (3)
Institutional Metric SIGA GOVX Criterion Row Edge
Market Capitalization
Scale
$187.9M $1.1M Larger Scale SIGA
Trailing P/E Ratio
Valuation
N/M 9.7x Lower Multiple GOVX
Forward P/E Ratio
Valuation
2.5x 9.7x Lower Multiple SIGA
Revenue Growth (YoY)
Growth
-49.7% -100.0% Higher Growth SIGA
Operating Margin (TTM)
Profitability
-14.2% 0.0% Higher Margin GOVX
Net Profit Margin
Profitability
1.3% 0.0% Higher Margin SIGA
Return on Equity (ROE)
Capital Efficiency
0.4% -891.6% Higher ROE SIGA
52-Week Range Position
Momentum
3% ($3–$7) 42% ($0–$4) Stronger Trend GOVX
Beta / 30D Volatility
Risk Regime
0.75β · 65% Vol 16.91β · 6225% Vol Lower Realized Risk SIGA
Unified Institutional Score
Composite Signal
47.5 / 100 (HOLD) 26.5 / 100 (SELL) Higher Composite SIGA
Trailing 12M Revenue (USD)
Operating Scale
$52M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
23.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.37x PEG · 1.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M ($116M Net Cash) N/A ($2.8M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GOVX +737.63 pp
SIGA: -15.06% · GOVX: +722.57%
3M Horizon GOVX +208.68 pp
SIGA: -12.83% · GOVX: +195.85%
6M Horizon GOVX +13.19 pp
SIGA: -43.74% · GOVX: -30.55%
1Y Horizon GOVX +423.75 pp
SIGA: -55.61% · GOVX: +368.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SIGA Revenue GOVX Revenue SIGA Op. Margin GOVX Op. Margin Margin Leader
FY2018 $480M $0M 74.4% -266.1% SIGA
FY2019 $30M $0M -8.7% -201.8% SIGA
FY2020 $120M $0M 67.6% -154.5% SIGA
FY2021 $130M $0M 66.7% -4862.7% SIGA
FY2022 $110M $0M 38.5% -17207.5% SIGA
FY2023 $140M N/A 59.8% N/A SIGA
FY2024 $140M $0M 50.4% -635.8% SIGA
FY2025 $90M $0M 25.1% -869.3% SIGA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SIGA CONSOLIDATION
33d in phase · OBV DISTRIBUTION
Current IV 81.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIGA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GOVX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GOVX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SIGA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $187.9M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($20M)
90D Engineering Disclosures 0 Published
GOVX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SIGA vs GOVX Key Questions & Quantitative Answers

As of Nov 19, 2026, SIGA Technologies Inc. (SIGA) is the stronger overall head-to-head candidate over GeoVax Labs, Inc. New (GOVX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SIGA carries a Unified Composite Score of 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin), whereas GOVX carries 26.5/100 (SELL) at $1.91 (9.7x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SIGA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0); meanwhile GOVX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 72.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SIGA leads the Growth & Scale pillar: SIGA posts -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin), compared with GOVX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SIGA cumulative revenue shifted -81.2% while GOVX shifted N/A. In operating R&D and SG&A reinvestment, SIGA deploys 37.6% of Rev ($20M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GOVX.

SIGA screens cheaper on headline valuation multiples. SIGA trades at 2.5x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin), whereas GOVX trades at 9.7x Forward P/E, 9.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SIGA (0.4% ROE) versus GOVX (-891.6% ROE) capital efficiency.

In options market volatility and institutional positioning, SIGA carries 81.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 65% Vol realized risk). By comparison, GOVX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (16.91β · 6225% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.